Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease.

Becker-Grünig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, Gorenflo M, Tiede H, Schranz D, Hager A, Kaemmerer H, Miera O, Ulrich S, Speich R, Uiker S, Grünig E.

Int J Cardiol. 2013 Sep 20;168(1):375-81. doi: 10.1016/j.ijcard.2012.09.036. Epub 2012 Oct 5.

PMID:
23041100
2.

Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension.

Nagel C, Prange F, Guth S, Herb J, Ehlken N, Fischer C, Reichenberger F, Rosenkranz S, Seyfarth HJ, Mayer E, Halank M, Grünig E.

PLoS One. 2012;7(7):e41603. doi: 10.1371/journal.pone.0041603. Epub 2012 Jul 25.

3.

Exercise training in pulmonary arterial hypertension associated with connective tissue diseases.

Grünig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, Fiehn C, Stöckl F, Prange F, Staehler G, Reichenberger F, Tiede H, Halank M, Seyfarth HJ, Wagner S, Nagel C.

Arthritis Res Ther. 2012 Jun 18;14(3):R148. doi: 10.1186/ar3883.

4.

Safety and efficacy of exercise training in various forms of pulmonary hypertension.

Grünig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C.

Eur Respir J. 2012 Jul;40(1):84-92. doi: 10.1183/09031936.00123711. Epub 2012 Feb 9.

5.

Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension.

Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M.

Respiration. 2011;81(5):394-401. doi: 10.1159/000322475. Epub 2011 Feb 9.

PMID:
21311162
6.

Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.

Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E.

Circulation. 2006 Oct 3;114(14):1482-9. Epub 2006 Sep 18.

7.

[Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].

Kaemmerer H, Gorenflo M, Hoeper M, Huscher D, Ewert P, Pittrow D.

Dtsch Med Wochenschr. 2013 Jun;138(23):1247-52. doi: 10.1055/s-0033-1343189. Epub 2013 May 29. Review. German.

PMID:
23720182
8.

Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial.

Ganderton L, Jenkins S, Gain K, Fowler R, Winship P, Lunt D, Gabbay E.

BMC Pulm Med. 2011 May 23;11:25. doi: 10.1186/1471-2466-11-25.

9.

The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension.

Kabitz HJ, Bremer HC, Schwoerer A, Sonntag F, Walterspacher S, Walker DJ, Ehlken N, Staehler G, Windisch W, Grünig E.

Lung. 2014 Apr;192(2):321-8. doi: 10.1007/s00408-013-9542-9. Epub 2013 Dec 13.

PMID:
24338088
10.

Economic evaluation of exercise training in patients with pulmonary hypertension.

Ehlken N, Verduyn C, Tiede H, Staehler G, Karger G, Nechwatal R, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Halank M, Grünig E.

Lung. 2014 Jun;192(3):359-66. doi: 10.1007/s00408-014-9558-9. Epub 2014 Mar 8.

PMID:
24609926
12.
13.

Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension.

Ley S, Fink C, Risse F, Ehlken N, Fischer C, Ley-Zaporozhan J, Kauczor HU, Klose H, Gruenig E.

Eur Radiol. 2013 Feb;23(2):324-31. doi: 10.1007/s00330-012-2606-z. Epub 2012 Aug 12.

PMID:
22886553
14.

Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.

Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.

Heart. 2007 Mar;93(3):350-4. Epub 2006 Sep 15.

15.
16.

Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).

Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB.

Am J Cardiol. 2014 Jan 1;113(1):147-55. doi: 10.1016/j.amjcard.2013.09.032. Epub 2013 Oct 4.

PMID:
24176071
17.

The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.

Zeng WJ, Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Gu Q, Zhao ZH, Li JJ, He JG; Sildenafil Therapy on Pulmonary Arterial Hypertension Associated With Different Types of Congenital Heart Disease Study Group.

Clin Cardiol. 2011 Aug;34(8):513-8. doi: 10.1002/clc.20917. Epub 2011 Jun 15.

18.

Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.

Diller GP, Dimopoulos K, Kaya MG, Harries C, Uebing A, Li W, Koltsida E, Gibbs JS, Gatzoulis MA.

Heart. 2007 Aug;93(8):974-6.

19.

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.

Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:25-31.

PMID:
16919007
20.

Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.

Monfredi O, Griffiths L, Clarke B, Mahadevan VS.

Am J Cardiol. 2011 Nov 15;108(10):1483-8. doi: 10.1016/j.amjcard.2011.07.006. Epub 2011 Sep 21.

PMID:
21943933
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk